Cargando…
Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
Dysregulation of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) signaling pathway is frequently observed in multiple human malignancies, and thus, therapeutic strategies targeting FGFs and FGFRs in human cancer are being extensively explored. We observed the activation o...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222839/ https://www.ncbi.nlm.nih.gov/pubmed/30326595 http://dx.doi.org/10.3390/molecules23102643 |
_version_ | 1783369300543799296 |
---|---|
author | Boichuk, Sergei Galembikova, Aigul Dunaev, Pavel Micheeva, Ekaterina Valeeva, Elena Novikova, Maria Khromova, Natalya Kopnin, Pavel |
author_facet | Boichuk, Sergei Galembikova, Aigul Dunaev, Pavel Micheeva, Ekaterina Valeeva, Elena Novikova, Maria Khromova, Natalya Kopnin, Pavel |
author_sort | Boichuk, Sergei |
collection | PubMed |
description | Dysregulation of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) signaling pathway is frequently observed in multiple human malignancies, and thus, therapeutic strategies targeting FGFs and FGFRs in human cancer are being extensively explored. We observed the activation of the FGF/FGFR-signaling pathway in imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) cells. Furthermore, we found that the activation of FGFR signaling has a significant impact on IM resistance in GISTs in vitro. Next, we tested the efficacy of BGJ398, a potent and selective FGFR1–3 inhibitor, in xenograft models of GISTs exhibiting secondary IM resistance due to receptor-tyrosine kinase (RTK) switch (loss of c-KIT/gain of FGFR2a). Five to eight-week-old female nu/nu mice were subcutaneously inoculated into the flank areas with GIST T-1R cells. Mice were randomized as control (untreated), IM, BGJ398, or a combination and treated orally for 12 days. IM had a moderate effect on tumor size, thus revealing GIST resistance to IM. Similarly, a minor regression in tumor size was observed in BGJ398-treated mice. Strikingly, a 90% decrease in tumor size was observed in mice treated with a combination of IM and BGJ398. Treatment with BGJ398 and IM also induced major histopathologic changes according to a previously defined histopathologic response score and resulted in massive myxoid degeneration. This was associated with increased intratumoral apoptosis as detected by immunohistochemical staining for cleaved caspase-3 on day 5 of the treatment. Furthermore, treatment with BGJ398 and IM significantly reduced the proliferative activity of tumor cells as measured by positivity for Ki-67 staining. In conclusion, inhibition of FGFR signaling substantially inhibited the growth of IM-resistant GISTs in vitro and showed potent antitumor activity in an IM-resistant GIST model via the inhibition of proliferation, tumor growth, and the induction of apoptosis, thereby suggesting that patients with advanced and metastatic GISTs exhibiting IM resistance might benefit from therapeutic inhibition of FGFR signaling. |
format | Online Article Text |
id | pubmed-6222839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62228392018-11-13 Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo Boichuk, Sergei Galembikova, Aigul Dunaev, Pavel Micheeva, Ekaterina Valeeva, Elena Novikova, Maria Khromova, Natalya Kopnin, Pavel Molecules Article Dysregulation of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) signaling pathway is frequently observed in multiple human malignancies, and thus, therapeutic strategies targeting FGFs and FGFRs in human cancer are being extensively explored. We observed the activation of the FGF/FGFR-signaling pathway in imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) cells. Furthermore, we found that the activation of FGFR signaling has a significant impact on IM resistance in GISTs in vitro. Next, we tested the efficacy of BGJ398, a potent and selective FGFR1–3 inhibitor, in xenograft models of GISTs exhibiting secondary IM resistance due to receptor-tyrosine kinase (RTK) switch (loss of c-KIT/gain of FGFR2a). Five to eight-week-old female nu/nu mice were subcutaneously inoculated into the flank areas with GIST T-1R cells. Mice were randomized as control (untreated), IM, BGJ398, or a combination and treated orally for 12 days. IM had a moderate effect on tumor size, thus revealing GIST resistance to IM. Similarly, a minor regression in tumor size was observed in BGJ398-treated mice. Strikingly, a 90% decrease in tumor size was observed in mice treated with a combination of IM and BGJ398. Treatment with BGJ398 and IM also induced major histopathologic changes according to a previously defined histopathologic response score and resulted in massive myxoid degeneration. This was associated with increased intratumoral apoptosis as detected by immunohistochemical staining for cleaved caspase-3 on day 5 of the treatment. Furthermore, treatment with BGJ398 and IM significantly reduced the proliferative activity of tumor cells as measured by positivity for Ki-67 staining. In conclusion, inhibition of FGFR signaling substantially inhibited the growth of IM-resistant GISTs in vitro and showed potent antitumor activity in an IM-resistant GIST model via the inhibition of proliferation, tumor growth, and the induction of apoptosis, thereby suggesting that patients with advanced and metastatic GISTs exhibiting IM resistance might benefit from therapeutic inhibition of FGFR signaling. MDPI 2018-10-15 /pmc/articles/PMC6222839/ /pubmed/30326595 http://dx.doi.org/10.3390/molecules23102643 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Boichuk, Sergei Galembikova, Aigul Dunaev, Pavel Micheeva, Ekaterina Valeeva, Elena Novikova, Maria Khromova, Natalya Kopnin, Pavel Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo |
title | Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo |
title_full | Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo |
title_fullStr | Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo |
title_full_unstemmed | Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo |
title_short | Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo |
title_sort | targeting of fgf-signaling re-sensitizes gastrointestinal stromal tumors (gist) to imatinib in vitro and in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222839/ https://www.ncbi.nlm.nih.gov/pubmed/30326595 http://dx.doi.org/10.3390/molecules23102643 |
work_keys_str_mv | AT boichuksergei targetingoffgfsignalingresensitizesgastrointestinalstromaltumorsgisttoimatinibinvitroandinvivo AT galembikovaaigul targetingoffgfsignalingresensitizesgastrointestinalstromaltumorsgisttoimatinibinvitroandinvivo AT dunaevpavel targetingoffgfsignalingresensitizesgastrointestinalstromaltumorsgisttoimatinibinvitroandinvivo AT micheevaekaterina targetingoffgfsignalingresensitizesgastrointestinalstromaltumorsgisttoimatinibinvitroandinvivo AT valeevaelena targetingoffgfsignalingresensitizesgastrointestinalstromaltumorsgisttoimatinibinvitroandinvivo AT novikovamaria targetingoffgfsignalingresensitizesgastrointestinalstromaltumorsgisttoimatinibinvitroandinvivo AT khromovanatalya targetingoffgfsignalingresensitizesgastrointestinalstromaltumorsgisttoimatinibinvitroandinvivo AT kopninpavel targetingoffgfsignalingresensitizesgastrointestinalstromaltumorsgisttoimatinibinvitroandinvivo |